ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

AstraZeneca To Build Biologics Plant

by Rick Mullin
May 25, 2015 | APPEARED IN VOLUME 93, ISSUE 21

AstraZeneca plans to invest about $285 million in a biological medicines manufacturing facility in Södertälje, Sweden. The plant, which will focus on filling and packaging protein therapeutics, will initially supply medicines for clinical trial programs for AstraZeneca and MedImmune, the drug company’s biologics R&D arm. The project could create between 150 and 200 jobs, according to the company, which already operates a tablet and capsule manufacturing site in Södertälje. AstraZeneca’s announcement closely follows Alexion Pharmaceuticals’ decision to build a $505 million biologics plant near Dublin, Ireland.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment